Clinical Trials Logo
  1. Home
  2. Impaired Glucose Tolerance
  3. NCT05215210

The Effect of Long-term Momordica Charantia Supplementation on Blood Glucose Levels — Bitter-Zoet 2  

Impaired Glucose Tolerance Clinical Trial

Official title:
The Effect of Long-term Momordica Charantia Supplementation on Blood Glucose Levels

Clinical Trial Summary

The study is a parallel, double blind, controlled trial in which study participants will receive a 12-week intervention with 3.6 g/d dried bitter-gourd supplements or a reference intervention with 3.6 g/d dried cucumber supplements. Research subjects will come to the research facility for a test day on four occasions, with an interval of 4 weeks. The main study parameter is fasting levels of plasma glucose.

Clinical Trial Description

Bitter gourd (BG) (Momordica charantia) is a highly nutritive vegetable from the cucumber family. The objective is to assess the impact of 12-weeks of BG supplementation on blood glucose levels in subjects with impaired fasting glucose levels. In a previous trial (Bitter-Zoet NL70259.081.19) the short-term effects of BG (4 weeks) were studied, but no effect was observed. In the current trial a different BG cultivar is chosen, the intervention period is prolonged, the dosage per day is higher and study subjects with slightly higher fasting blood glucose levels will be included. The study is a parallel, double blind, controlled trial in which study participants will receive a 12-week intervention with 3.6 g/d dried bitter-gourd supplements or a reference intervention with 3.6 g/d dried cucumber supplements. Research subjects will come to the research facility for a test day on four occasions, with an interval of 4 weeks. The main study parameter is fasting levels of plasma glucose. Secondary outcome measures are glucose tolerance, HbA1c, insulin and HOMA-IR and HOMA-B levels. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT05215210
Study type Interventional
Source Wageningen University and Research
Contact
Status Completed
Phase N/A
Start date March 23, 2022
Completion date June 30, 2022
View Details
See also
  Status Clinical Trial Phase
Recruiting NCT05354245 - Using a Complex Carbohydrate Mixture to Steer Fermentation and Improve Metabolism in Adults With Overweight and Prediabetes (DISTAL) N/A
Completed NCT04088461 - Effect of Linagliptin + Metformin on Patients Who do Not Achieve Normoglucemia With Metformine Phase 4
Completed NCT02621060 - Effect of Chlorogenic Acid on Patients With Impaired Glucose Tolerance Phase 2
Completed NCT01488279 - Effect of Sitagliptin on Short-Term Metabolic Dysregulation of Oral Glucocorticoid Therapy N/A
Completed NCT01521312 - ACute and Chronic Effects of Saxagliptin Phase 2
Completed NCT01559896 - Egg Protein Hydrolysate and Vascular Function N/A
Completed NCT01030978 - Prevention of Type 2 Diabetes in Children With a Family-based Healthy Lifestyle Program N/A
Completed NCT00573781 - Dietary Modulation of Gene Expression and Metabolic Pathways in Glucose Metabolism Phase 2
Terminated NCT00846521 - Study of Post-meal Blood Sugar Peaks in Association With Vascular Disease in Childhood Obesity Phase 4
Completed NCT00241072 - Clinical Trial To Evaluate The Effect Of Valsartan On Insulin Sensitivity In Subjects With Impaired Glucose Tolerance Phase 4
Completed NCT00536250 - Study to Investigate the Pathophysiology of Type 2 Diabetes in Youth N/A
Completed NCT02254317 - Dose-dependent Effect of Grape Seed Extract on Glucose Control in People With Impaired Glucose Tolerance N/A
Completed NCT03764423 - Health Effects of Salmon Fishmeal in Humans N/A
Recruiting NCT05347030 - Acupuncture for Impaired Glucose Tolerance in Overweight/Obese Population N/A
Active, not recruiting NCT04341571 - Effect of Probiotics Versus Metformin on Glycemic Control, Insulin Sensitivity and Insulin Secretion in Prediabetes. Phase 2
Completed NCT02700334 - Effect of Dapagliflozin on Insulin Secretion and Insulin Sensitivity in Patients With Prediabetes Phase 4
Active, not recruiting NCT01933529 - ARA290 in T2D (Effects of ARA 290, an Erythropoietin Analogue) in Prediabetes and Type 2 Diabetes) Phase 2
Completed NCT02135172 - Breaks in Sedentary Time and Glucose Regulation in Women N/A
Active, not recruiting NCT01841229 - Effect of Ginseng on Glycemic Control N/A
Completed NCT02248272 - Effect of Meal Frequency on Glycemic Control of People at High Risk or Diagnosed With Diabetes N/A